The number of drug-resistant tuberculosis (TB) cases is rising globally. But a newly discovered natural antibiotic — produced by bacteria from the lung infection in a cystic fibrosis patient — could help fight these infections.
Lab testing reported in the Journal of the American Chemical Society shows that the compound is active against multi-drug resistant strains.
Starting with the famous first discovery of penicillin from mold, scientists have continued to search for natural sources of antibiotics. And as pathogens develop resistance to once-reliable medicines, the search has taken on a new urgency. By 2040, more than a third of all TB cases in Russia, for example, could show resistance to first-line drugs currently used to fight the disease, a recent report published in Lancet estimates. Among potential new drug sources are species of the bacterial genus Burkholderia that thrive in a wide range of habitats, from soil to the human lung. One way these microbes have adapted to these diverse environments is by making potent antibiotics to take out their competition. In light of the growing threat of drug-resistant bacteria, particularly among TB strains, Gregory L. Challis, Eshwar Mahenthiralingam and colleagues wanted to see if Burkholderia might produce a promising anti-TB compound.
The researchers discovered that one species, Burkholderia gladioli, which was isolated from the sputum of a child with cystic fibrosis, produces an antibiotic called gladiolin. The compound belongs to the same structural class as etnangien, another antibiotic that has been investigated for its ability to jam bacterial cell machinery. But etnangien is highly unstable. The researchers found that gladiolin is much more stable than etnangien, and could therefore potentially be a better drug candidate. Lab testing also showed that gladiolin blocked the growth of four drug-resistant TB strains.
[osd_subscribe categories=’tuberculosis’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “TUBERCULOSIS”‘]
The Latest on: Antibiotic-resistant TB
[google_news title=”” keyword=”antibiotic-resistant TB” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Antibiotic Resistance Causes More Deaths Than Malaria And HIV/Aids Combined. What Africa Is Doing To Fight This Silent Epidemicon February 29, 2024 at 7:14 pm
In Africa, drug resistance is already a documented problem for HIV, malaria, tuberculosis (TB), typhoid, cholera, meningitis, gonorrhoea and dysentery . How big a problem is antimicrobial resistance?
- VinBrain inks deal to transfer AI technology for tuberculosis screeningon February 29, 2024 at 12:20 am
VinBrain has signed a commercial agreement with Global Fund to transfer AI technology for TB screening and detection.
- What it takes to push tuberculosis elimination across the finish lineon February 27, 2024 at 4:00 pm
It’s very important that every individual who has TB disease is identified, diagnosed, put on treatment, and completes the treatment. In fact, this 30% gap in diagnoses even increases to almost 60% ...
- Drug-resistant tuberculosis responds rapidly to bedaquiline-based second-line therapyon February 27, 2024 at 11:17 am
Patients who have drug-resistant tuberculosis (TB) have a similar microbiological response to bedaquiline-based second-line medications as patients with drug-sensitive TB taking first-line regimens, ...
- Fight against TB persists in PH as disease remains a threaton February 27, 2024 at 3:05 am
Despite significant medical advances making tuberculosis (TB) preventable and usually curable, over 10 million people globally continue to contract the disease annually, ...
- Second-line treatment for drug-resistant tuberculosis is as effective as first-line medicineson February 26, 2024 at 4:00 pm
In 2012, the United States Food and Drug Administration approved bedaquiline, the first new TB drug in four decades, leading the WHO to update treatment guidelines for drug-resistant TB in 2018.
- 76% of TB patients received payment for nutritional supporton February 24, 2024 at 7:40 am
Analysis of Ni-kshay Poshan Yojana direct benefit transfer program for TB patients in India, highlighting delays and improvements.
- Why have efforts to eradicate TB been so slow?on February 19, 2024 at 9:11 pm
In stark contrast, tuberculosis TB has persisted for centuries, yet many people in the developed world remain largely unaware of it, and vaccine development has received little attention.A new push ...
- Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: Current Status and Future Prospectson February 9, 2024 at 4:00 pm
Drug resistance in Mycobacterium tuberculosis arises from the man-made selection of mutants that result from spontaneous chromosomal alterations. Preventing the development of drug-resistant TB ...
- Welch Foundation grant supports UTA research on drug-resistant tuberculosison February 1, 2024 at 4:00 pm
This new drug-resistant TB can lead to a new infection in the original patient, who can then spread the disease-resistant TB to other people. Drug-resistant TB is much more difficult to treat ...
via Google News and Bing News